Hello NMPA: China Approval For Astellas's Xtandi, Keytruda Set For Fourth Indication
Executive Summary
Astellas’s Xtandi gets its latest approval in China, where Merck’s Keytruda is set for another win.
You may also be interested in...
After US Approval, BeiGene Set To Gain Sixth PD-1 Green Light In China
Beijing-based BeiGene is set to score two big wins in a row as it pursues innovation. After securing US approval for its BTK inhibitor zanubrutinib for mantle cell lymphoma, its PD-1 inhibitor has sailed through a technical review in China.
Strong Xtandi Drives Astellas To Brighter Outlook
Japanese firm unveils new capital investment program for novel biologics including antibodies and cell therapies as it ups full-year forecasts on strong US and global growth for Xtandi after a solid first half.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.